Slides on Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP

Learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
person default
Jason Schafer, PharmD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 1.09 MB
Released: February 16, 2022

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

Dr Kenric Ware discusses considerations for ongoing PrEP candidacy and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 20, 2023

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this commentary from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 19, 2023

In this case-based video module, Dr Jill Blumenthal shares key data and recommendations about PrEP in transgender young adults, from Clinical Care Options (CCO)

Jill Blumenthal, MD, MAS Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 9, 2023 Expired: January 8, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings